
### **Plenary Speakers**

Partial list of confirmed speakers.

#### **NEXT GENERATION RNA BASED THERAPEUTICS**



### THE FUTURE OF PD THERAPY; WHY MULTI TARGET DRUGS

Moussa Youdim (Israel)

CSF AND BLOOD BIOMARKERS FOR AD - PATHOPHYSIOLOGY, DIAGNOSTIC ALGORITHMS AND THERAPY MONITORING

Kaj Blennow (Sweden)

TRANSLATIONAL NEUROPATHOLOGY: BEGINNING AT THE END TO INFORM THE BEGINNING

Melissa Murray (USA)

CONSIDERATION OF BLOOD-BASED BIOMARKERS FOR COMMUNITY SCREENING — INFLUENCE OF

### COMORBIDITIES, RACE/ETHNICITY, AND SEX

Michelle Mielke (USA)

## DISEASE MODIFIERS FOR ALZHEIMER'S DISEASE - A REGULATORY PERSPECTIVE

Yaning Wang (USA)

# THE FIRST DISEASE-MODIFYING TREATMENTS FOR AD: A GLASS HALF FULL

Denis Selkoe (USA)